Selected reaction monitoring (SRM) and multiple reaction monitoring (MRM) are the same triple-quadrupole targeted logic used in proteomics to quantify a closed peptide list by liquid chromatography-tandem mass spectrometry (LC-MS/MS). Quadrupole 1 isolates a precursor m/z, the collision cell fragments that ion population, and quadrupole 3 passes selected product ions so only predefined transitions are recorded (Lange et al. 2008). Relative same-peptide peak areas are the default claim. Absolute amount needs matched stable isotope-labeled standards (SIS) and a stated calibration model. SRM/MRM is not open discovery like data-dependent acquisition (DDA) or data-independent acquisition (DIA), and it does not establish clinical diagnostic cutoffs without a separately validated assay framework.

Researchers who already have a closed peptide panel or a validation objective can also review the MtoZ Biolabs SRM-MRM Quantitative Proteomics Services and Targeted Proteomics Service for project-specific feasibility and assay planning.

Principle: What SRM and MRM Measure

In proteomics, SRM historically names monitoring of a selected precursor-to-product pair. MRM names monitoring of multiple such pairs in one method, which is the usual laboratory practice for multi-peptide panels. Neither name by itself specifies chromatography, dwell time, or whether an SIS was used.

The quantitative object is the chromatographic peak area of locked transitions for proteotypic peptides chosen from discovery data, spectral libraries, or literature. Proteins outside the inclusion list remain invisible even if they are abundant. Qualifier transitions help check interference at unit-resolution Q3, where co-eluting isobars can still share nominal masses.

Figure 1. SRM/MRM quantifies predefined precursor-to-product transitions for a closed peptide list; it does not survey the full proteome.

An SRM/MRM signal is the peak area of scheduled transitions, not a discovery inventory.

For principle-level depth beyond this overview, see Principle of Multiple Reaction Monitoring. For platform comparison with PRM, see PRM and MRM in Targeted Proteomics: Advantages and Limitations and PRM vs. MRM: Comparative Analysis in Quantitative Proteomics.

Workflow: From Closed List to Reported Claim

A workable SRM/MRM project follows a fixed order. Skipping transition validation cannot be repaired by higher sample load alone.

1. Close the peptide and transition list

Select unique proteotypic peptides where possible. Define quantitative and qualifier transitions, collision energies, and retention-time windows before the cohort is queued.

2. Decide relative versus absolute readout

Same-peptide areas support relative confirmation when digestion and loading stay comparable. Absolute concentration needs matched SIS peptides, with spike timing recorded. An SIS added after failed digestion cannot reconstruct the lost protein.

3. Prepare matched digests and acquire

Extract, digest, and clean up under one protocol. Separate peptides by liquid chromatography and cycle through the transition list with declared dwell times. Review peak shape, retention-time drift, and qualifier ratios in software such as Skyline.

4. Report only the stated claim

Integrate accepted peaks and report relative confirmation or SIS-based amount. Statistical contrasts and pathway maps are downstream interpretation. They do not convert a closed list into discovery coverage.

Figure 2. The SRM/MRM workflow locks transitions before acquisition; absolute claims require SIS and calibration, while relative claims still need matched processing.

For the shared targeted path, see Targeted Proteomics Workflow: How Does Targeted Proteomics Work?. For absolute designs, see Absolute Quantification in Targeted Proteomics and Advantages and Disadvantages of AQUA Technique.

Judgment Criteria: When SRM/MRM Fits

Study need	SRM/MRM often fits	Reassess before scheduling
Target status	Closed, mature peptide and transition list	Open discovery inventory still required
Throughput	High-multiplex panel must run repeatedly	Fragments still under review; PRM may fit better
Claim	Relative confirmation; absolute with SIS	Diagnostic cutoff without validated assay framework
Matrix	Transitions proven clean in the study matrix	Severe interference with no alternate peptides
Upstream path	DDA/DIA or literature already nominated candidates	No discovery support and no literature panel

Prefer SRM/MRM when transitions are locked and multiplex production throughput matters. Prefer parallel reaction monitoring (PRM) when full high-resolution MS2 and post-run fragment choice are needed for a moderate panel (Peterson et al. 2012). Prefer DDA or DIA while the protein inventory is still open. Prefer AQUA-style SIS designs when defined concentration units are required.

Figure 3. Choose SRM/MRM after the peptide list is closed; keep discovery or change to PRM or AQUA when the claim differs.

For why MRM is often discussed for accurate quantification, see Why Is MRM the Preferred Method for Accurate Quantification in Mass Spectrometry?. For PRM-focused confirmation, see How PRM Proteomics Supports Biomarker Validation.

Limits and Application Boundaries

SRM/MRM cannot recover proteins that were never scheduled. Unit-resolution interference can still admit background ions. Ion suppression and retention-time drift remain matrix and chromatography limits. Calling every targeted result clinically diagnostic overstates ordinary research reporting.

Typical applications:

• Biomarker candidate confirmation after discovery shortlisting.
• Multiplex monitoring of a locked protein panel across treatment or genotype arms.
• Pharmacodynamic or process protein panels that need repeated high-throughput runs.
• Absolute peptide amount when SIS peptides and calibration are built into the method.

Environmental pollutant or small-molecule SRM assays outside proteomics use the same transition logic but are separate method classes with different sample prep. Diagnostic cutoffs and companion-diagnostic claims sit outside ordinary research SRM/MRM reporting unless a separately validated assay framework is in place.

Once the peptide list, transition set, and relative or absolute claim are defined, the project can be scoped as an SRM/MRM study. Researchers can review the MtoZ Biolabs SRM-MRM Quantitative Proteomics Services and Parallel Reaction Monitoring (PRM) Service for sample evaluation and assay planning.

Frequently Asked Questions

1. Are SRM and MRM different methods in proteomics?

In practice they share the same triple-quadrupole transition logic. SRM emphasizes a selected pair; MRM names multi-transition panels.

2. Can SRM/MRM discover new proteins?

No. Only scheduled peptides are measured. Open inventories still need DDA, DIA, or related discovery routes.

3. Does SRM/MRM automatically give absolute concentration?

No. Absolute units require matched SIS peptides and calibration. Peak areas alone remain relative.

4. When should a project prefer PRM over MRM?

When fragment review in complex matrices matters more than maximum multiplex on a locked transition panel.

5. Is SRM/MRM the same as a clinical diagnostic assay?

Not by default. Research confirmation and multiplex monitoring still need separate analytical validation before diagnostic cutoffs.

Reference

1. V. Lange, P. Picotti, B. Domon, R. Aebersold (2008). Selected reaction monitoring for quantitative proteomics: a tutorial. Mol. Syst. Biol., 4, 222. https://doi.org/10.1038/msb.2008.61
2. A.C. Peterson, J.D. Russell, D.J. Bailey, M.S. Westphall, J.J. Coon (2012). Parallel reaction monitoring for high resolution and high mass accuracy quantitative, targeted proteomics. Mol. Cell. Proteomics, 11, 1475-1488. https://doi.org/10.1074/mcp.O112.020131